Navigation Links
Cystic Fibrosis Foundation funds Marshall research
Date:3/28/2011

HUNTINGTON, W.Va. The Cystic Fibrosis Foundation has awarded a Marshall University scientist a two-year, $194,400 grant.

The grant to Dr. Hongwei Yu, professor in the Department of Biochemistry and Microbiology at the university's Joan C. Edwards School of Medicine, will help further his lab's work to explore the factors that control the overproduction of mucus in the lungs of cystic fibrosis (CF) patients.

According to Yu, chronic bronchial pneumonia caused by the bacterium Pseudomonas aeruginosa is a life-threatening condition for patients with CF.

"During these infections in CF patients, the bacterium is capable of producing copious amounts of alginatea thick, sugar-like polymer that plugs the airways, making breathing difficult," he said. "The alginate also helps form a thick, slimy 'biofilm' around the colonies of bacteria, protecting them from the body's immune defense mechanisms and making antibiotic treatment less effective."

Yu said the long-range goal of his research is to better understand the mechanisms of how this bacterium regulates production of the alginate biofilms in order to develop a more effective treatment option to inhibit or suppress the formation of alginate biofilms in the lungs of CF patients.

"For this project, we will be accessing the relevance of two newly identified proteins that act as alginate regulators. Once the mechanisms controlling alginate production are fully understood, it may be possible to improve treatment of these bacterial infections in CF patients by modulating or suppressing that production," he added.

Dr. John Maher, Marshall's vice president for research, congratulated Yu and praised him and his team for obtaining the grant.

"Dr. Yu's work is an excellent example of the vital research here at Marshall University that can affect the health and welfare of people everywhere. Research in his lab has the potential to have a real impact on the quality of life for people with cystic fibrosis," said Maher.

Maher also noted that Yu's research has had a regional economic development impact, saying his work has led to a patent and the development of Progenesis Technologies LLC, a West Virginia-based biotech research and development company. A second patent is pending.


'/>"/>

Contact: Ginny Painter
ginny.painter@marshall.edu
30-474-611-964
Marshall University Research Corporation
Source:Eurekalert  

Related biology news :

1. Pig model of cystic fibrosis improves understanding of disease
2. Breakthrough on cystic fibrosis 1 step closer as new research alliance formed
3. Women with polycystic ovary syndrome may be more vulnerable to BPA
4. Common diabetes drug may halt growth of cysts in polycystic kidney disease
5. 1 step closer to a drug treatment for cystic fibrosis, MU professor says
6. Drug may treat cystic fibrosis, other diseases caused by nonsense mutations, UAB researcher says
7. Research project yields better understanding of the defective protein that causes cystic fibrosis
8. Cystic fibrosis testing -- next steps
9. Two-pronged model could help foil tough cystic fibrosis infections
10. Nanoemulsion potent against superbugs that kill cystic fibrosis patients
11. New test promises quicker, more accurate evaluation for cystic fibrosis patients
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cystic Fibrosis Foundation funds Marshall research
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... Parallel ... clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module ... circle with the physician and clinical trial team. , Using the CONSULT module, patients ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in ... Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio ... practical tips, tools, and strategies for clinical researchers. , “The landscape of how ...
Breaking Biology Technology: